Document:

Amendment Agreement dated December 14, 2006

 EXHIBIT 10.8J 
 AMENDMENT AGREEMENT 
 This Amendment Agreement
(the “Amendment”) is made as of the 14th day of December, 2006 (the “Amendment Effective Date”),
between SmithKline Beecham Corporation, doing business as GlaxoSmithKline Corporation, a corporation of the Commonwealth of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101 (“GSK”) and NPS
Pharmaceuticals, Inc., a corporation of the State of Delaware, having a place of business at Morris Corporate Center 1, 300 Interpace Parkway, Parsippany, NJ 07054 (“NPS”). 
 WHEREAS, GSK and NPS previously entered into a Collaborative Research and License Agreement effective November 1, 1993 (the “Original
Agreement”) and various amendments thereto (the “Subsequent Amendments”; the Original Agreement and Subsequent Amendments collectively referred to herein as the “Agreement”); and 
 WHEREAS, by letter dated December 9, 2003 (the “2003 Amendment”), the parties further amended the Agreement to provide for, among other
things, the termination of the Agreement’s Research term and the identification of a total of six (6) calcilytic Compounds from the Amino Alcohol Series (as defined below) for which GSK desired to pursue Development, four of which were
identified in the 2003 Amendment and are set forth on Appendix One hereto, 
 WHEREAS, GSK may pursue Development of calcilytic
Compounds from the Amino Alcohol Series that are yet to be identified by GSK in addition to the Compounds set forth on Appendix One (all such Compounds from the Amino Alcohol Series referred to herein as the “Development
Compounds”); and 
 WHEREAS, GSK and NPS now desire to enter into this Amendment to amend the Agreement and 2003 Amendment and
memorialize the terms upon which NPS will grant to GSK the right and license to pursue Development of calcilytic Compounds in addition to the Development Compounds; 
 NOW THEREFORE, GSK and NPS agree to amend the terms of the Agreement and 2003 Amendment as follows: 
  

	1.	Capitalized terms used herein retain the meaning given them in the Agreement unless otherwise stated. Except to the extent otherwise expressly provided herein, the terms of the
Agreement and 2003 Amendment shall remain in force and effect. 

  

	2.	The “Amino Alcohol Series” shall mean those Compounds set forth on Appendix One and structurally related Compounds. 

  

	3.	The definition of NPS Net Sales is hereby amended to include sales of Compounds by NPS in accordance with Section 13.07 (set forth below), such sales to occur upon termination
of the Agreement in accordance with Section 12.08(c), as amended herein. 

  

	4.	For the avoidance of doubt, GSK has the right to select any number of Development Compounds at any time during the term of the Agreement from the Amino Alcohol Series, which will be
subject to all the terms of the Agreement. 

  

	5.	A nonrefundable, non-creditable of three millions U.S. Dollars ($3,000,000) will be paid by GSK to NPS, upon receipt of an invoice from NPS, upon the earlier to occur of either
(a) December 31, 2006 or (b) Candidate Selection. For purposes of this Paragraph 5, “Candidate Selection” will mean the date upon which it is determined by GSK, in its sole discretion, that a Compound meets the criteria
applicable for Second Stage Development Studies. The applicable milestone payment will be made within fifteen (15) business days of the date of the invoice provided by NPS to GSK. If the applicable milestone achieved is Candidate Selection, the
GSK will give NPS prompt written notification of the occurrence of Candidate Selection, but in no event will such notice be given to NPS more than ten (10) business days after achievement of Candidate Selection. 

  

	6.	The last sentence of Section 2 of the 2003 Amendment is hereby deleted and deemed null and void. For the avoidance of doubt, the parties agree that the scope of the licenses
granted to GSK by NPS under Article 4 of the Agreement includes, but is not limited to, GSK’s right to make, have made, use, sell, offer for sale and import all Compounds, and is not restricted to any particular chemical class of Compounds.

	7.	Section 4 of the 2003 Amendment is hereby deleted and deemed null and void. The Development Compounds shall be subject to the terms of the Agreement including but not limited
to the payment by GSK of milestones and royalties as set forth in Article 5 and NPS’s rights of co-promotion as set forth in Section 4.05 and Article 9. Notwithstanding the foregoing, and subject to the milestone to be paid under Paragraph
5 of this Amendment, the parties acknowledge and agree that the only remaining milestone payable with respect to all of the Development Compounds is a one-time payment of five million U.S. Dollars ($5,000,000) for the first of the Development
Compounds for which an NDA is filed with the FDA, such payment to be made in accordance with the applicable terms of the Agreement. 

  

	8.	Section 9 of the 2003 Amendment is hereby deleted and deemed null and void. The parties agree that the scope of the licenses granted to GSK by NPS under Article 4 of the
Agreement include GSK’s right to make, have made, use, sell, offer for sale and import all Compounds, without limitation. Any Compounds other than the Development Compounds are subject to the terms of the Agreement including but not limited to
the payment of royalties as set forth in Article 5 and NPS’s rights of co-promotion as set forth in Section 4.05 and Article 9; provided, that in lieu of the milestone payments described in Section 5.01 of the Agreement, GSK will pay
NPS the following payments upon achievement of the applicable milestone, upon receipt by GSK of an invoice from NPS and within thirty (30) days of the occurrence of such milestone with respect to a Compound other than the Development Compounds:

  

				
	 Submission of an IND to the FDA
	  	U.S. $	 2,000,000
	 Acceptance of NDA filing for review by FDA
	  	U.S. $	 5,000,000
	 NDA Approval by the FDA
	  	 	U.S.$20,000,000

 For the avoidance of doubt, the foregoing payments shall be payable only one time with respect to
the first such Compound that is not a Development Compound to attain a milestone event, and no payment will be made for milestones that are not achieved. 
  

	9.	Section 12.08(c) of the Agreement is hereby deleted and deemed null and void and will be replaced in its entirety by the following: 

 “NPS may terminate this Agreement upon ninety (90) days prior written notice to GSK if no Compound is in Development or under commercialization
by GSK for a period of twelve (12) consecutive months. Upon receipt of such written notice, GSK will have forty-five (45) days from the receipt of such notice to verify to NPS that it either (i) is commercializing a Compound,
(ii) has a Compound in active Development or (iii) intends to have a Compound enter Development within six (6) months. If GSK reasonably demonstrates such intent to the reasonable satisfaction of NPS, there shall be no such
termination.” 
  

	10.	A new Section 13.07 is hereby added to the Agreement as follows: 

 “13.07 If this Agreement is terminated by NPS in accordance with Section 12.08(c), then the following shall apply: 
 (a) All rights and licenses granted by NPS to GSK will terminate; 
 (b) All of NPS’s interest and rights in Patents, Research Information and Know-How owned solely by NPS will fully revert to NPS;

 (c) GSK will assign promptly to NPS all regulatory filings and regulatory approvals and all data, materials and information
supporting such regulatory approvals, owned by GSK that relate solely to a Compound, or if such assignment is not legally permissible, grant NPS the right to access, use and cross-reference such filings, approvals and data; 
  

 2 

 (d) GSK will grant to NPS a non-exclusive right and license to use Patents owned solely
by GSK, and GSK’s interests in Patents owned jointly by GSK and NPS, solely related to Compounds and necessary to develop, manufacture or commercialize a Compound, and 
 (e) NPS will assume complete responsibility for the preparation, filing, prosecution and maintenance of all Patents owned solely by NPS,
and all costs associated therewith in a prompt manner. NPS may request that GSK provide such reasonable assistance as is necessary to NPS in such efforts and GSK shall be entitled to reimbursement for any and all costs incurred by GSK in such
efforts. 
 Upon termination of the Agreement in accordance with Section 12.08(c), and in consideration for the transfer of rights to NPS
under Section 13.07, if NPS subsequently commercializes a Compound previously under Development by GSK, NPS will pay to GSK a royalty of five percent (5%) of worldwide NPS Net Sales of the Compound billed or invoiced by NPS or its
Affiliates or licensees, in accordance with Section 18.07 of this Agreement. Royalties would be payable on a country-by-country basis, commencing upon the launch of such Compound in such country by NPS, its Affiliates or a permitted licensee,
until the later of either (a) ten (10) years from the date of first launch of such Compound in such country, or (b) the expiration, or invalidation by a court or other legal or administrative tribunal from which no appeal is or can be
taken of the last Patent in such country which contains a valid and unexpired claim covering the sale of such Compound.” 
  

	11.	A new Section 13.08 is hereby added to the Agreement as follows: 

 “If after the termination of the Agreement pursuant to Section 12.08(c), and the subsequent transfer of rights to NPS as set forth in Section 13.07, NPS desires to sell or offer for sale in the
Territory a Compound abandoned by GSK, then NPS will give GSK written notice of such desire, and GSK will have an exclusive right of first negotiation to obtain such rights on an exclusive basis. Such written notification will include all relevant
data and information required to enable GSK to make an informed decision. With ninety (90) days of GSK’s receipt of NPS’s written notice, GSK shall notify NPS whether it desires to pursue an exclusive arrangement for such rights. If
GSK so notifies NPS, then GSK shall have, for a period of sixty (60) days thereafter (the “Negotiation Period”) the exclusive right to negotiate the terms of such exclusive arrangement. If no agreement is reached within the
Negotiation Period, then NPS shall not, within the three (3) month period thereafter, offer to, or accept from any third party, any terms that are less favorable on the whole to NPS than the last terms offered by GSK without first offering such
terms to GSK. Thereafter, NPS may pursue discussions with third parties with respect to such commercialization rights.” 
  

	12.	The last sentence of Section 15.01(b) of the Agreement is hereby deleted in its entirety. 

  

	13.	Section 15.03 of the Agreement is hereby amended to read as follows: 

 “15.03 (a) Each party shall promptly notify the other upon the making, conceiving or reducing to practice of any invention or discovery referred to in Section 15.02. With respect to any such invention,
GSK shall have the first right, using in-house or outside legal counsel selected at GSK’s sole discretion, to prepare, file, prosecute, maintain and extend patent applications and patents concerning all such inventions and discoveries, whether
owned in whole by GSK or NPS, or jointly by GSK and NPS in countries of GSK’s choice throughout with appropriate credit to NPS representatives, including the naming of such parties as inventors where appropriate and in accordance with the
relevant legal requirements, for which GSK shall bear the costs relating to such activities which occur at GSK’s request or direction. GSK may request that NPS provide such reasonable assistance as is necessary to GSK in such efforts and NPS
shall be entitled to reimbursement for any and all costs incurred by NPS in such efforts after the Amendment Effective Date. 
 (b) If GSK, prior or subsequent to filing certain patent applications on any inventions or discoveries which are owned in whole or in part by NPS, elects not to file, prosecute or maintain such patent applications or ensuing patents or
certain claims encompassed by such patent applications or ensuing patents in any country of the Territory, GSK shall give NPS notice thereof within a reasonable period prior to allowing such patent applications or patents or such certain claims
encompassed by such patent applications or patents to lapse or become abandoned or unenforceable, and NPS shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain patent applications and patents or divisional
applications related to such certain 
 claims encompassed by such patent applications or patents concerning all such inventions and
discoveries in countries of its choice throughout the world. 
  

 3 

 (c) The party filing patent applications for jointly owned inventions and discoveries
shall do so in the name of and on behalf of both GSK and NPS. Each of NPS and GSK shall hold all information it presently knows or acquires under this Paragraph 15.03 which is related to all such patents and patent applications as confidential
subject to the provisions of Article 14. 
 (d) In furtherance of this Section 15.03, for so long as GSK is the party
responsible for preparing, filing, prosecuting, maintaining and extending patents and patent applications in the Territory, if NPS receives any communications from any patent office in the Territory, it will promptly inform GSK of such communication
or provide such communication to GSK.” 
  

	14.	Section 15.06, as set forth in the 2003 Amendment, is hereby amended to read as follows: 

 “15.06 Beginning on the Amendment Effective Date, NPS and GSK shall meet at least once each calendar year to review the status of all Patents being
prosecuted by either NPS or GSK. In addition, NPS shall adhere to the publication review provisions set forth in Section 14.07 in order to permit GSK to protect any confidential or potentially patentable information that may be contained
therein.” 
  

	15.	For the avoidance of doubt, the term “Development” as used herein has the meaning ascribed to it in the 2003 Amendment, and includes First Stage Development or Second
Stage Development. 

  

	16.	Any conflicts between this Amendment and the 2003 Amendment will be resolved in favor of this Amendment. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized officers or representatives. 
  

									
	SmithKline Beecham Corporation	 	 	 	NPS Pharmaceuticals, Inc.
	(d/b/a GlaxoSmithKline)	 		 	
					
	By:	 	 /s/ DONALD PARMAN
	 		 	By:	 	 /s/ N. ANTHONY COLES

	Title:	 	Vice President and Secretary	 		 	Title:	 	President & CEO

  

 4Separation Agreement dated November 10, 2006

 EXHIBIT 10.25 
 SEPARATION AGREEMENT 
 This Separation Agreement documents the agreement between Edward F. Nemeth and
NPS Pharmaceuticals, Inc., its subsidiaries and affiliates (“NPS” or “the Company”) concerning the termination of Dr. Nemeth’s status as an employee of the Company. 
 RECITALS 
  

	 	A.	Dr. Nemeth has been employed by the Company as its Vice President and Chief Scientific Officer, through and including the Separation Date (as defined below).

  

	 	B.	Dr. Nemeth and the Company have entered into a number of agreements governing employment and severance of that employment including, but not limited to, the following:

  

	 	(i)	Employee Agreement Concerning Invention Assignment, Non-Disclosure and Non-Competition (“Non-Disclosure and Non-Competition Agreement”), a copy of which is attached as
Exhibit A. 

  

	 	(ii)	Agreement Providing Specified Benefits Following Termination of Employment Incident to Merger, Acquisition or Other Change of Control or Some Other Strategic Corporate Event
(“Termination Agreement”), a copy of which is attached as Exhibit B. 

  

	 	(iii)	Indemnity Agreement, a copy of which is attached as Exhibit C. 

  

	 	C.	Dr. Nemeth and the Company have agreed to terminate Dr. Nemeth’s employment under the Termination Agreement, and have concluded that he is entitled to receive the
severance benefits provided in paragraph 2 of the Termination Agreement. 

 Based on the foregoing Recitals, and on the mutual
covenants contained herein, Dr. Nemeth and the Company agree as follows: 
 1. Separation Date. Dr. Nemeth’s status as
an employee of the Company is terminated effective the close of business on November 10, 2006 (the “Separation Date”). 
 2.
Severance and Benefits. The severance and benefits to which Dr. Nemeth is entitled as of the Separation Date are as follows: 
 2.1 Severance Pay. The Duration of Severance Period under said Termination Agreement is twenty-four months including, but not limited to, the salary benefit as provided under paragraph 2.1 of the
Termination Agreement. With respect to such salary benefits, the Company will pay to Dr. Nemeth severance pay in a total amount of CAD $796,000 (the “Severance Payment”), which amount is equal to 24 months gross straight-line salary,
as follows: 
  

	 	•	 	 The Company will pay to Dr. Nemeth the Severance Payment, less applicable withholding taxes, within seven (7) days after the expiration of the Revocation
Period referenced in Section 18 below, provided that this Agreement is not revoked by Dr. Nemeth during such Revocation Period. 

  

	 	•	 	 The Company agrees to direct up to the maximum allowable amount of the Severance Payment to a Registered Retirement Savings Plan in the name of Dr. Nemeth and
such allowable amount will not be subjected to withholding taxes. 

 2.2 Insurance. Dr. Nemeth,
his spouse and eligible family members, will continue to receive medical and/or dental coverage in accordance with paragraph 2.2 of the Termination Agreement and which will be paid by the Company for 18 months from the Separation Date. 

 

 1 

 2.3 Stock Options. Effective on the first day after the Separation Date, as
provided for under paragraph 2.3 of the Termination Agreement, Dr. Nemeth’s outstanding stock options, as shown on the Option Grant Status Report (attached hereto as Exhibit D), will receive accelerated vesting and continued exercisability
for the longer of (i) 24 months (the Duration of the Severance Period), from the Separation Date, or (ii) such other period as he may be entitled to under any stock option plan or grant or retirement plan. Following the Separation
Date, and after any applicable accelerated vesting, all unvested options will immediately expire. 
 2.4 Business Related
Expenses. In accordance with its Expense Reimbursement Policy, the Company will reimburse Dr. Nemeth for all reasonable and proper business-related expenses incurred by Dr. Nemeth prior to the Separation Date and attributable to
Dr. Nemeth’s service to the Company through the Separation Date. Dr. Nemeth will reimburse the Company for any non-cancellable expenses, including without limitation airfare, car service, hotel expenses, and meeting fees, incurred by
the Company on behalf of Dr. Nemeth for any period after the Separation Date. The Company will deduct any expense reimbursable by Dr. Nemeth from the Severance Payment under Section 2.1 above. 
 3. Confidential Information. The terms of the Non-Disclosure and Non-Competition Agreement will continue in effect after the Separation Date.
Under that agreement, Dr. Nemeth is required to protect and not disclose any information regarding the Company’s proprietary intellectual property, its financial condition, terms of its business relations, and all other Confidential
Information as defined in that agreement. 
 4. Property. It is understood that anything produced by Dr. Nemeth as an
employee of the Company is the property of the Company. Dr. Nemeth is obligated to leave with or return to the Company any such documents whether tangible property or in electronic form belonging to the Company including, but not limited to,
documents or tangible property which may contain or reflect confidential information or trade secrets of the Company. Such confidential information and trade secrets may include scientific data, proprietary ideas, financial information, knowledge of
specific business dealings or practices, or other matters which the Company attempts to maintain as confidential in the course of its business. By the signatures below, Dr. Nemeth certifies to the Company that he has returned all property of
the Company. 
 5. Life Insurance. The Company currently is the owner of a group term life insurance policy that includes
Dr. Nemeth, which may be converted to an individual policy (with certain limitations). A conversion form will be provided by the insurance carrier to Dr. Nemeth with benefits information. Any supplemental life insurance may also be
converted to an individual policy. 
 6. Personal Time Off (PTO). PTO will continue to be accrued through the Separation Date and
Dr. Nemeth will be paid in cash for all unused PTO, up to twenty days. 
 7. Short- and Long-Term Disability Insurance. All
Company arrangements for payment, either direct or through insurance, for short-term disability and long-term disability, will cease on the Separation Date. 
 8. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, public policy or may subject Dr. Nemeth to the payment of
additional tax under Section 409A, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transaction contemplated hereby is not affected in any
manner materially adverse to either party. Upon such determination that any term or other provision is invalid, illegal, incapable of being enforced or may subject Dr. Nemeth to the payment of additional tax under Section 409A, the parties
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent
possible and, to the extent applicable, then do not constitute nonqualified deferred compensation subject to the requirements of Section 409A or satisfy such requirements. the Company has advised Dr. Nemeth to seek his own business and
legal advice concerning the terms hereof. 
 9. Release. In consideration of receiving the benefits described herein,
Dr. Nemeth and all persons claiming by, through or under him, hereby releases and discharges the Company, its subsidiaries, affiliates, 

  

 2 

 
successors, assigns, agents, directors, officers, employees, representatives, attorneys and all persons acting by, through, under or in concert with it
(hereinafter collectively referred to as “Releasees”), of and from any and all claims, demands, charges, grievances, damages, debts, liabilities, accounts, costs, attorneys’s fees, expenses, liens and causes of action for the
following: (i) libel, slander, discrimination and other claims under applicable Canadian law and U.S. law, including without limitation, The Age Discrimination in Employment Act, The Older Workers” Benefit Protection Act, Title VII of the
Civil Rights Act of 1964, the Fair Labor Standards Act, The Americans With Disabilities Act, The Utah Antidiscrimination Act, The Workers’ Adjustment and Retraining Notification Act (WARN Act), The Employee Retirement Income Security Act
(ERISA) and all other laws prohibiting age, race, religion, sex, national origin, color, disability and other forms of discrimination, whether now known or unknown, suspected or unsuspected, including future rights, and (ii) arising out of the
employment relationship between Dr. Nemeth and the Company, and (iii) arising prior to the Separation Date. Provided however, that Dr. Nemeth does not release the Company from claims for dishonesty, fraud, embezzlement, criminal act
or willful misconduct. This release does not affect obligations contained herein, nor does it vitiate Dr. Nemeth’s obligations under the Non-Disclosure and Non-Competition Agreement, or any Company stock option plan, benefit or grant to
which Dr. Nemeth may be entitled as of the Separation Date. 
 10. No Right to Reinstatement. It is understood and agreed
that, in return for the consideration described herein, Dr. Nemeth will not be eligible for future employment with the Company and that, should he apply for employment, the Company shall have no obligation to consider him for any position.

 11. Nondisparagement. Dr. Nemeth agrees not to disparage the Company or any of its directors, officers or employees in any
manner harmful to the Company’s business or business reputation. Dr. Nemeth further agrees that as of the Separation Date, he shall not represent himself or hold himself out as a current employee or officer of the Company, or as holding
any other current position with the Company other than pursuant to any further agreement between the Company and Dr. Nemeth, specifically any consulting agreement. The Company agrees that it will not disparage Dr. Nemeth in any manner
harmful to his reputation, provided that the Company shall not be precluded from confirming to others Dr. Nemeth’s separation as an employee from the Company. This paragraph will not prevent Dr. Nemeth or the Company from describing
this separation if required in connection with compliance filings or administrative or judicial proceedings. 
 12.
References. The Company will provide Dr. Nemeth with a letter of reference that will include the starting and ending dates of Dr. Nemeth’s employment with the Company and an explanation of the position held with the
Company. 
 13. Nonparticipation in Legal or Administrative Proceedings. Dr. Nemeth covenants that he will not file, nor
voluntarily participate or assist in the prosecution of any legal or administration proceedings against the Company or any related entities and their respective directors, officers and employees, provided that nothing in this paragraph shall prevent
his participation in any such proceeding in compliance with a summons that requires such participation. 
 14. Future
Employment/Consulting. Subject to the provisions of this Agreement and the Non-Disclosure and Non-Competition Agreement, Dr. Nemeth may accept a position, as an employee or consultant, with: Kirin Brewery Co., Ltd. of Tokyo; Amgen, Inc.;
GlaxoSmithKline Corporation; or Marical Inc. and such position may relate directly or indirectly to technologies licensed to the aforementioned companies by the Company. 
 15. Consequences of Violation of this Agreement. If either party hereto violates any of the promises contained in this Agreement, then that party shall pay for all costs incurred by any of the released
parties, including reasonable attorneys’ fees. 
 16. Knowing and Voluntary Agreement. Each party hereto represents,
declares, and agrees that he or it voluntarily accepts the provisions of this Agreement for the purposes of making a full and final compromise, adjustment and settlement of all claims herein described. Dr. Nemeth has been advised to consult an
attorney and understands the effect of signing this Agreement. 
 17. Entire Agreement. This Agreement, when executed, contains
the entire agreement between the parties and there are no other understandings or agreements, written or oral, between them on the subject except as 

  

 3 

 
expressly stated herein. The Recitals are an integral part of this Agreement. This Agreement fully supersedes and replaces any and all prior agreements or
understandings, if any, on any matter that is addressed in this Agreement, with the exception that it is agreed that the Non-Disclosure and Non-Competition Agreement and Indemnity Agreement remain in effect in accordance with its terms. This
Agreement cannot be amended or modified except by a written document signed by both parties. 
 18. Review and Revocation
Periods. Dr. Nemeth acknowledges and understands that this is a legal document and that he is legally entitled to, and has been offered, a period of twenty-one (21) days (the “Consideration Period”) to consider the waivers
and releases made by him in this Agreement before signing it. Dr. Nemeth further acknowledges and agrees that either the full Consideration Period has lapsed or he has been offered such Consideration Period but has elected to waive and forego
all of the applicable days which have not yet lapsed in such Consideration Period. This Agreement shall not become effective until seven calendar days after the date of execution by Dr. Nemeth (the “Revocation Period”). During the
Revocation Period, Dr. Nemeth may revoke this Agreement by notifying the Company in writing. Upon expiration of the Revocation Period, this Agreement becomes final and binding. Dr. Nemeth acknowledges that he has had an adequate amount of
time in which to consult with any person with respect to the contents of this Agreement prior to signing. 
 19. Confidential
Treatment. Dr. Nemeth and the Company agree that the terms of this Agreement are confidential and will not be disclosed to others except as required by law or as necessary to implement the terms hereof. 
 20. Governing Law. This Agreement shall be interpreted and enforced in accordance with the laws of the Province of Ontario. 
 The parties have executed this Agreement as of the dates set forth below. 
  

									
	 	 	 	 	 	 	 	 	NPS PHARMACEUTICALS, INC.
				
	 /s/ EDWARD F. NEMETH
	 		 	By:	 	 /s/ VAL R. ANTCZAK

	Edward F. Nemeth	 		 		 	 Val R. Antczak,
 Senior Vice President, Legal Affa
irs

					
	Date:	 	  
	 		 		 	
		 		 		 	Date:	 	  

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]